Exelixis reported $275.36M in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
Agios Pharmaceuticals USD -109.2M 540K Jun/2026
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Amgen USD 5.8B 1.25B Sep/2026
AstraZeneca USD 7.46B 2.3B Sep/2026
Bayer EUR 1.62B 529M Sep/2026
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Cytokinetics USD -160.3M 9.02M Jun/2026
Eisai JPY 25.94B 8.21B Sep/2026
Eli Lilly USD 9.46B 3.54B Sep/2026
Exelixis USD 275.36M 19.96M Sep/2026
Genmab DKK 401M 186M Jun/2026
Glaxosmithkline GBP 2.93B 154M Sep/2026
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -95.22M 9.99M Sep/2026
MacroGenics USD -64.54M 34.34M Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Moderna USD -687M 571M Jun/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
Novartis USD 8.62B 2.14B Sep/2026
Pfizer USD 6.36B 350M Sep/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Sanofi EUR 6.66B 4.99B Sep/2026
Takeda JPY 369.75B 5.29B Sep/2026
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Xencor USD 25.1M 59.73M Sep/2026